Related Experiment Video
Updated: Jun 17, 2025
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Assessing the causal relationship between plasma proteins and osteoporosis: novel insights into pathological
Liang Wang1, Xiangyun Guo1, Jinran Qin1
1School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Abstract:
Identifying dysregulated plasma proteins in osteoporosis (OP) progression offers insights into prevention and treatment. This study found 8 such proteins associated with OP, suggesting them as therapy targets. This discovery may cut drug development costs and improve personalized treatments.
Purpose:
This study aims to identify potential therapeutic targets for OP using summary data-based Mendelian randomization (SMR) and colocalization analysis methods. Furthermore, we seek to explore the biological significance and pharmacological value of these drug targets.
Methods:
To identify potential therapeutic targets for OP, we conducted SMR and colocalization analysis. Plasma protein (pQTL, exposure) data were sourced from the study by Ferkingstad et al. (n = 35,559). Summary statistics for bone mineral density (BMD, outcome) were obtained from the GWAS Catalog (n = 56,284). Additionally, we utilized enrichment analysis, protein-protein interaction (PPI) network analysis, drug prediction, and molecular docking to further analyze the biological significance and pharmacological value of these drug targets.
Results:
In the SMR analysis, while 20 proteins showed significance, only 8 potential drug targets (GCKR, ERBB3, CFHR1, GPN1, SDF2, VTN, BET1L, and SERPING1) received support from colocalization (PP.H4 > 0.8). These proteins are closely associated with immune function in terms of biological significance. Molecular docking also demonstrated favorable binding of drugs to proteins, consistent with existing structural data, further substantiating the pharmacological value of these targets.
Conclusions:
The study identified 8 potential drug targets for OP. These prospective targets are believed to have a higher chance of success in clinical trials, thus aiding in prioritizing OP drug development and reducing development costs.
Insights
Researchers identified 8 plasma proteins linked to osteoporosis (OP) progression. These proteins may serve as novel therapeutic targets, potentially reducing drug development costs and improving personalized osteoporosis treatments.
Area of Science:
- Genetics and Bioinformatics
- Pharmacology
- Immunology
Background:
- Osteoporosis (OP) is a significant health concern, and identifying novel therapeutic targets is crucial for effective prevention and treatment.
- Dysregulated plasma proteins are implicated in OP progression, offering potential avenues for intervention.
Purpose of the Study:
- To identify potential therapeutic targets for osteoporosis using summary data-based Mendelian randomization (SMR) and colocalization analysis.
- To explore the biological significance and pharmacological value of the identified drug targets.
Main Methods:
- Summary data-based Mendelian randomization (SMR) and colocalization analysis were employed.
- Plasma protein quantitative trait loci (pQTL) data and bone mineral density (BMD) genome-wide association study (GWAS) summary statistics were utilized.
- Enrichment analysis, protein-protein interaction (PPI) network analysis, drug prediction, and molecular docking were performed for further validation.
Main Results:
- Eight proteins (GCKR, ERBB3, CFHR1, GPN1, SDF2, VTN, BET1L, and SERPING1) were identified as potential drug targets for OP, supported by colocalization analysis.
- These targets are significantly associated with immune function, indicating their biological relevance.
- Molecular docking confirmed favorable drug-protein binding, supporting their pharmacological value.
Conclusions:
- The study successfully identified 8 novel potential drug targets for osteoporosis.
- These targets show promise for clinical trials, potentially accelerating OP drug development and reducing associated costs.
- This research contributes to personalized medicine approaches for osteoporosis treatment.
More Related Videos
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Related Concept Videos
01:40Bone Remodeling
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:16Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...